Brief: EMA's CHMP Says Opinion Recommending Marketing Authorisation For Leqembi Not Need To Be Updated

Krystal Biotech

28/02/2025 12:44

Feb 28 (Reuters) - EMA's CHMP:

EMA'S CHMP: VYJUVEK (BEREMAGENE GEPERPAVEC) RECEIVE POSITIVE OPINION TO TREAT WOUNDS IN PATIENTS OF ALL AGES WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

EMA SAYS CHMP:  CONCLUDED THAT ITS OPINION RECOMMENDING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) DOES NOT NEED TO BE UPDATED

EMA'S CHMP: EXTENSION TO EXISTING INDICATION OF CHIKUNGUNYA VACCINE IXCHIQ TO INCLUDE ACTIVE IMMUNISATION OF ADOLESCENTS FROM 12 YEARS OF AGE

EMA'S CHMP: FABHALTA GETS POSITIVE OPINION FOR EXTENSION OF INDICATION FOR TREATMENT OF ADULT PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY

EMA'S CHMP:  RECOMMENDS APPROVAL OF DEQSIGA FOR PRIMARY, SECONDARY IMMUNODEFICIENCIES AND AUTOIMMUNE DISEASE IMMUNOMODULATION

Source text: [ID:]

Further company coverage: KRYS.O

 ((Reuters.Briefs@thomsonreuters.com;))